Ethynyl derivatives
US10065956B2 · kind B2 · utility
4Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2017 |
| Grant date | Sep 4, 2018 |
| Priority date | — |
| Expiry date | Sep 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2. Compounds of formula I are representative, where substituents are defined herein: or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.